Data from Pharmawand - Curated by EPG Health - Date added 05 January 2019

The National Institute for Health and Care Excellence has recommended that Fasenra (benralizumab), from AstraZeneca, be available to people with severe eosinophilic asthma on the NHS in England and Wales. The therapy is given with a dosage as an injection every four weeks for the first three doses, and every eight weeks thereafter. This makes it potentially more convenient than Nucala (mepolizumab), which is also injected, but every four weeks.

In an earlier appraisal consultation document, NICE had concluded that the drug was not cost-effective, but an improved patient access scheme from AZ helped overturn this position.

Comments

You will need to login, to leave a comment.

epgonline.org is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Sleep Apnea

Sleep Apnea

Sleep apnea is a chronic condition characterised by recurrent interruptions in breathing throughout the sleep cycle. Learn about the two main types of sleep apnea and hear from experts as they present the latest research at the Sleep and Breathing conference (Marseille, 2019).

Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

View highlights from recent congresses presented in new expert videos with leading physicians.

+ 7 more

Cystic Fibrosis Knowledge Centre

Cystic Fibrosis Knowledge Centre

View disease awareness information, treatment options and European Cystic Fibrosis Society best practice guidelines.

Load more

Related Content